Epitalon (Epithalon): Telomerase Claims vs Evidence, Dosage, Safety, Status

Key takeaways

• Epitalon (also spelled epithalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, designed in St. Petersburg as a stand-in for epithalamin, an extract of calf pineal glands. It is sold as a telomerase activator and longevity drug.
• The telomere evidence is cell culture: the developers' lab in 2003 and an independent UK lab in 2025 reported longer telomeres in human cells in a dish. No study has measured telomere length in a person taking epitalon, and no human trial has measured aging, disease or lifespan.
• In the main mouse study, average lifespan did not change; the longest-lived tenth lived about 13% longer. The human reports are few, small, mostly unblinded and largely from the developer's institute; the best of them found a 1.7-fold rise in a urinary melatonin marker in about 20 women, with sleep never measured.
• The dose gap: websites FDA reviewed list 5 to 10 mg a day, 10 to 20 times the 0.5 mg a day used under the tongue in the only placebo-controlled human study. There are no human pharmacokinetic or long-term safety data, and FDA's reviewers flagged a theoretical cancer risk from switching on telomerase.
• Not FDA-approved and not compoundable. It left FDA's Category 2 list on April 15, 2026, and FDA's advisory committee voted 7 to 4 to recommend it in July 2026 against FDA staff advice, but no rule has been issued, so no licensed US pharmacy may make it.

Epitalon at a glance

Also called

Epithalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly, epitalon acetate

Class

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on epithalamin, a calf pineal gland extract; proposed to activate telomerase and modulate melatonin rhythms in cell and animal studies

Route

Under the skin or into muscle in animal studies; a sublingual spray and an injection beside the eye in the few human reports; no human pharmacokinetic data

FDA status

Not FDA-approved. FDA placed it in Category 2 (significant safety risk) in September 2023 and removed it on April 15, 2026 after the nomination was withdrawn; its advisory committee voted 7 to 4 with 1 abstention in July 2026 to recommend it for the 503A list against FDA reviewers' advice. No rule has been issued, so it cannot be legally compounded.

FDA Category 2 (compounding restricted)

No

Available by prescription (US)

No legal US source: there is no approved product, and no 503A pharmacy or 503B facility may compound it in October 2026

Best-studied use

Cell and animal studies of telomerase, lifespan and tumors; small human reports on a urinary melatonin marker (sublingual spray) and retinitis pigmentosa (injection beside the eye), mostly from the developer's institute

Typical monthly cost (telehealth, 2026)

No legal product exists to price; research vials are unapproved drugs and we do not list their prices

What epitalon is and how it works

Epitalon is a tetrapeptide: alanine, glutamic acid, aspartic acid and glycine, with a molecular weight of about 390. Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology built it from the amino-acid makeup of epithalamin, a polypeptide extract of calf pineal glands the same group had studied for years. FDA treats epitalon and epithalamin as different substances (FDA epitalon review 2026), and that matters: some of the most quoted human results, including the mortality reports, used the extract.

Three mechanisms are proposed, all from cells and animals.

1. Telomerase. Telomeres are protective caps on chromosome ends that shorten with each cell division; telomerase is the enzyme that rebuilds them. Khavinson's lab reported that adding epitalon to telomerase-negative human fetal fibroblasts switched on the enzyme's catalytic subunit and lengthened telomeres (Khavinson 2003), and that treated cells made 10 extra divisions past the point where untreated cells stopped, 44 passages against 34 (Khavinson 2004).
2. Melatonin rhythm. In old female rhesus monkeys, epitalon raised evening melatonin and restored the daily rhythm of cortisol (Goncharova 2001). How it would do this is unknown; FDA notes that rat pineal glands bathed in epitalon in the laboratory did not release more melatonin (FDA epitalon review 2026).
3. Gene regulation. The developers propose that short peptides enter the cell nucleus and bind DNA and histone proteins, switching genes on and off. Independent researchers cite this as a possible explanation for their cell results (Al-Dulaimi 2025); nobody has shown it produces an effect in a person.

What is missing is basic pharmacology. There are no human pharmacokinetic data: nobody has published how long epitalon lasts in the blood, how much of an injection or a sublingual spray is absorbed, or where it goes (FDA epitalon review 2026).

What the evidence actually shows

The epitalon literature runs to dozens of papers, but it is narrow. Almost all of it comes from Khavinson's institute and close collaborators, much of it in Russian journals or their English translations, and the human part is a handful of small reports. Here is the grading.

Epitalon claims, graded by the evidence behind them

Claim	Grade	What the evidence shows	Sources
Activates telomerase and lengthens telomeres in human cells	D	In a dish, in two labs. The developers reported telomerase activation and longer telomeres in fetal fibroblasts. An independent UK lab found longer telomeres in two normal human cell lines after 3 weeks at 1 microgram per mL, and found that two breast-cancer cell lines also lengthened their telomeres, through a different mechanism (ALT).	Khavinson 2003; Khavinson 2004; Al-Dulaimi 2025
Lengthens telomeres in people	D	Never measured in a person given epitalon. The closest study incubated blood cells from 11 men with it in a dish: telomeres lengthened in 5, shortened in 2 and did not change significantly in 4.	Khavinson 2019
Extends lifespan	D	Mice only, and inconsistent. In 54 female SHR mice given about 1 microgram five days a month for life, mean lifespan did not change; the longest-lived 10% lived 13.3% longer and maximum lifespan was 12.3% longer. In female CBA mice given 0.1 microgram on the same schedule, mean survival rose 5.3%.	Anisimov 2003; Anisimov 2001
Prevents cancer	D	Mouse-only and mixed. Leukemia was 6-fold less common in SHR mice but total tumor incidence did not change; in HER-2/neu mice bred to develop breast cancer, tumors were fewer per mouse and smaller. FDA judged the studies too short (about 22 weeks of actual dosing at most), female-only and single-dose to rule cancer risk in or out.	Anisimov 2003; Anisimov 2002; FDA epitalon review 2026
Restores melatonin	C	In about 20 women aged 40 to 50 with low melatonin output, mostly night-shift workers, a sublingual spray at 0.5 mg a day for 20 days raised a urinary melatonin metabolite 1.7-fold while placebo did not; blinding was not described. Evening melatonin rose more than 4-fold in old monkeys after 10 daily injections.	Ivko 2020; Goncharova 2001; FDA epitalon review 2026
Improves sleep or treats insomnia	D	Never measured. FDA evaluated epitalon for insomnia in 2026 and found no human study in people with insomnia and no animal study with a sleep outcome.	FDA epitalon review 2026
Treats retinitis pigmentosa	B	The developers reported a positive clinical effect in 90% of patients with degenerative retinal disease treated with injections beside the eye. The abstract describes no placebo, randomization or blinding, and no independent group has repeated it.	Khavinson 2002; FDA epitalon review 2026
Lowers death rates in older people	C	Reported only for the extract epithalamin, not synthetic epitalon. In 266 older people followed 6 to 8 years, the developers reported 1.6- to 1.8-fold lower mortality with epithalamin, and 4.1-fold lower with yearly epithalamin plus a thymus extract. No randomization, blinding or placebo is described.	Khavinson & Morozov 2003
Safe for long-term use	D	Unknown. FDA found no clinical study assessing safety, no human pharmacokinetic data, and no acute, repeat-dose, reproductive or two-year cancer studies in animals.	FDA epitalon review 2026

Three things stand out from that table.

The source. One institute and its collaborators produced nearly all of it. The 2025 study from Brunel University London is the only independent replication of the telomere finding we found, and it was done in cell lines grown flat on plastic, which its authors named as the main limitation. They still wrote that epitalon "can be safely used in healthy individuals" (Al-Dulaimi 2025), a conclusion no cell culture can support.

The substance. The largest human numbers, the mortality reports, belong to epithalamin, an animal extract. Quoting them for synthetic epitalon is like quoting a trial of a plant extract for one molecule isolated from it.

The outcomes. Telomerase in a dish and a melatonin metabolite in urine are mechanisms. No study has measured an outcome a buyer cares about (aging, disease, lifespan, sleep) in people taking epitalon. A small randomized, placebo-controlled study exists, but it measured a urine marker for 20 days.

What you are promised versus what is documented

Websites FDA reviewed describe epitalon as a "fountain of youth" and list benefits from slower aging and longer life to better skin, deeper sleep, cancer and dementia prevention, immune support, eye health, energy and mood (FDA epitalon review 2026). The evidence sorts them into three bins.

• Documented in humans, weakly: a rise in a urinary melatonin marker in women with low melatonin output; better retinal findings in an unblinded report by the developers.
• Shown only in cells or animals: telomerase activation and longer telomeres; longer maximum (not average) lifespan in mice; fewer tumors in some mouse strains; higher evening melatonin in old monkeys.
• Not supported at all: slowing or reversing human aging, longer human life, better sleep, skin, muscle repair, prevention of dementia or heart disease, energy and mood.

Telomere lengthening deserves its own warning, because longer is not automatically better. In a Mendelian randomization study covering 35 cancers and 48 other diseases, with more than 420,000 cases, people genetically disposed to longer telomeres had higher risks of several cancers (odds ratios per standard deviation of 5.27 for glioma, 3.19 for lung adenocarcinoma and 1.87 for melanoma) and a lower risk of coronary heart disease (Haycock 2017). That trade-off is the reason FDA's reviewers worried about a drug sold to switch telomerase on.

Epitalon versus the realistic alternatives

For most people asking about epitalon, the honest comparison is with sermorelin, the other peptide sold for sleep and aging and the one a licensed pharmacy can make; our epitalon vs sermorelin comparison sets them side by side. The MOTS-c profile covers the other headline longevity peptide, and the longevity ranking grades all of them.

Dosage: what was studied versus what sellers list

The seller range is 10 to 20 times the only human dose with a placebo group, given by a different route, and it is taken daily, while the mice behind the lifespan claims were dosed five days a month. Our epitalon dosage guide works through the studied doses, a labeled mouse-to-human conversion and the seller charts in detail.

We give no reconstitution example. The reconstitution calculator is for medications a pharmacy has dispensed with a labeled concentration; an epitalon research vial has neither, and FDA has treated reconstitution guides and calculators on vendor websites as evidence that such vials are drugs sold for human use.

Side effects and who should not use it

What is known: almost nothing. FDA found no clinical study that assessed epitalon's safety. The night-shift study reported no safety data, and a 2007 abstract said the pineal preparations had "no side effects" without saying how anyone looked (FDA epitalon review 2026). FDA's adverse event database held no reports through December 2025, which means little: FDA itself notes that reporting is voluntary and that compounders generally do not report adverse events.

What FDA's reviewers raised:

• Cancer. Epitalon is sold to activate telomerase and lengthen telomeres, and long telomeres are associated with higher cancer risk; the mouse studies were too short and too narrow to settle it (FDA epitalon review 2026). The independent 2025 study adds a cell-level signal: breast-cancer lines exposed to epitalon lengthened their telomeres (Al-Dulaimi 2025). At the July 2026 committee meeting, opponents pressed exactly this point (HPM 2026).
• Immune reactions. Peptides can clump and carry synthesis impurities, and injected peptides can provoke antibodies; nobody has looked for them with epitalon.
• Not knowing what is in the vial. FDA found epitalon not well characterized: it is a common name rather than an official one, sold as a free base or an acetate salt, and the certificates of analysis it saw lacked tests for specific impurities, bacterial endotoxins or microbial load.
• No reproductive or long-term data in animals of any kind.

Short peptides are not harmless by default. In the same breast-cancer mouse experiment in which epitalon reduced tumors, the group's other synthetic peptide, Vilon, increased them (Anisimov 2002).

Do not use epitalon if you have an active cancer or a history of cancer, are pregnant, trying to conceive or breastfeeding, or are under 18. If you want it for sleep, see a clinician first: chronic insomnia and sleep apnea have treatments that work, set out in our sleep guide. For everyone else, the practical answer in October 2026 is that there is no legal, labeled product to use. The general picture of peptide risks is in our peptide side effects guide.

Legal status in the United States

The sequence, consistent with our legal tracker and our Category 2 explainer:

• Not an approved drug, and no basis for compounding. Epitalon has no USP monograph and is not a component of any FDA-approved drug (FDA epitalon review 2026), and it is not on the 503A bulks list. It fails all three tests a 503A pharmacy needs.
• September 29, 2023. FDA placed it in Category 2, substances that may present significant safety risks, citing immune reactions and no safety information for the proposed route.
• April 15, 2026. FDA announced it was one of twelve peptides leaving Category 2 because the nominations had been withdrawn. Removal ended the safety flag; it did not make epitalon compoundable (Frier Levitt 2026).
• July 24, 2026. FDA evaluated epitalon for one use, insomnia, and its reviewers recommended against listing it, citing poor characterization, no evidence of effectiveness for insomnia, no human safety data and immunogenicity concerns (FDA epitalon review 2026). The Pharmacy Compounding Advisory Committee voted 7 in favor, 4 against, with 1 abstention, to recommend it anyway; members in the majority said they were applying compounding criteria rather than drug-approval standards (HPM 2026).
• Since then. The vote is advisory. FDA must publish a proposed rule, take comments and finalize it before a pharmacy may use epitalon, and as of October 2026 no proposed rule has appeared.

Cost: there is no legal product to price

Because no licensed pharmacy may make epitalon, there is no prescription price to report, and we do not list research-vial prices. A telehealth program that bundles epitalon into a "longevity" plan is selling a research vial with a consultation attached; our guide to whether telehealth can prescribe peptides explains how to spot it, and the cost guide covers what legitimate peptide therapy costs.

What to do instead depends on why you were looking:

• For sleep: an evaluation, cognitive behavioral therapy for insomnia and, if needed, approved medication; see the sleep guide.
• For low growth hormone output with symptoms: sermorelin, prescribed with IGF-1 measured before and after.
• For longevity in general: the longevity ranking, which puts the peptides with outcome data first, and the complete guide to peptide therapy for how a legitimate prescription works.

Women and older adults

The only placebo-controlled human study enrolled women aged 40 to 50, most of them night-shift workers, and measured a melatonin marker for 20 days (Ivko 2020); there are no data in menopause or in older women. All three mouse lifespan and tumor studies used females only (FDA epitalon review 2026). Older adults are the market epitalon is sold to, and they are also the group with the highest background cancer risk, which makes the untested question of what lifelong telomerase activation does more pressing, not less.

Bottom line

Epitalon has the longest story of any longevity peptide and one of the thinnest evidence bases. Its telomere claim rests on cells in a dish, confirmed once by an independent lab that also saw cancer cells lengthen their telomeres. Its lifespan claim rests on mice whose average lifespan did not change. Its human data are a urine marker in about 20 women, an unblinded eye study and mortality reports for a different substance. Nobody has measured how it behaves in the human body, and FDA's reviewers named a plausible cancer risk that no study has ruled out.

In October 2026 it is also a product no US pharmacy may make. The July committee vote moved it one step toward the permitted list, over FDA staff objections, and that step is not a prescription. A reasonable position is to watch the Federal Register and the evidence; an unreasonable one is to inject a research vial for a telomere result seen in a petri dish.

Frequently asked questions

+−What is epitalon?

Epitalon, also spelled epithalon, is a synthetic peptide of four amino acids (Ala-Glu-Asp-Gly) designed by a St. Petersburg research group as a stand-in for epithalamin, an extract of calf pineal glands. It is sold as a longevity peptide that switches on telomerase. It is not FDA-approved, and in October 2026 no US pharmacy may compound it.

+−Does epitalon lengthen telomeres?

In cells in a dish, two labs say yes: the developers in 2003 and an independent UK group in 2025, which also found that breast-cancer cell lines lengthened their telomeres. No study has measured telomere length in a person taking epitalon. When blood cells from 11 men were incubated with it, telomeres lengthened in 5, shortened in 2 and did not change significantly in the other 4.

+−Does epitalon extend lifespan?

Not in any study of people. In the main mouse study, average lifespan did not change, although the longest-lived 10% of mice lived 13.3% longer; in another mouse strain mean survival rose 5.3%. The reports of lower death rates in older people used the pineal extract epithalamin, not synthetic epitalon, and did not describe randomization, blinding or a placebo.

+−Is epitalon good for sleep?

There is no evidence that it is. FDA reviewed epitalon for insomnia in 2026 and found no study of it in people with insomnia. A sublingual spray raised a urinary melatonin marker 1.7-fold in women with low melatonin output, and daily injections raised evening melatonin in old monkeys, but neither study measured sleep.

+−Is epitalon legal in the US?

Possessing it is not a crime, but it is not FDA-approved and no licensed pharmacy may compound it in October 2026. It left FDA's Category 2 list on April 15, 2026, and FDA's advisory committee voted 7 to 4, with 1 abstention, in July 2026 to recommend adding it to the permitted list, against the advice of FDA's reviewers. FDA has not issued a rule, so vials sold online are unapproved drugs.

+−Can a doctor prescribe epitalon?

A clinician can write the word on a prescription, but no 503A pharmacy or 503B outsourcing facility may legally fill it, because epitalon is not a component of an approved drug, has no USP monograph and is not on FDA's list of permitted bulk substances. A clinic that 'prescribes' epitalon in 2026 is supplying a research vial.

+−What are the side effects of epitalon?

Nobody knows. FDA found no clinical study that assessed its safety, no human pharmacokinetic data and no long-term animal toxicity or cancer studies. Its reviewers flagged two theoretical risks: immune reactions to impurities or clumped peptide in an injection, and cancer, because switching on telomerase and lengthening telomeres is what many cancer cells do.

+−Is epitalon the same as epithalamin?

No. Epithalamin is a mixture of peptides extracted from calf pineal glands; epitalon is a single synthetic four-amino-acid peptide modeled on it. FDA treats them as different substances. Several of the human results quoted for epitalon, including the mortality reports, used epithalamin.

+−Are longevity peptides legitimate?

Some of the science is real; the products mostly are not. Epitalon has decades of Russian research behind it, but its case for slowing aging rests on cell culture, mice and small unblinded reports, and it has no legal US product. No peptide has been shown to slow human aging; the peptides with hard-outcome trials are the GLP-1 drugs, which treat obesity and its consequences.

Sources

1. StudyKhavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003;135:590-2. (2003)
2. StudyKhavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med 2004;137:503-6. (2004)
3. StudyKhavinson VK et al. Effect of peptide AEDG on telomere length and mitotic index of PHA-stimulated human blood lymphocytes. Bull Exp Biol Med 2019;168:141-4. (2019)
4. StudyAl-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025;26:178 (figures corrected November 2025). (2025)
5. StudyAnisimov VN, Khavinson VK, Mikhalski AI, Yashin AI. Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mech Ageing Dev 2001;122:41-68. (2001)
6. StudyAnisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003;4:193-202. (2003)
7. StudyAnisimov VN et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer 2002;101:7-10. (2002)
8. StudyGoncharova ND, Khavinson VKh, Lapin BA. Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys. Bull Exp Biol Med 2001;131:394-6. (2001)
9. StudyKhavinson V et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett 2002;23:365-8. (2002)
10. StudyIvko OM et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Adv Gerontol 2020;33:429-35 (in Russian; English edition 2021). (2020)
11. StudyKhavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003;24:233-40. (2003)
12. StudyTelomeres Mendelian Randomization Collaboration; Haycock PC et al. Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study. JAMA Oncol 2017;3:636-51. (2017)
13. RegulatoryFDA. Evaluation of epitalon-related bulk drug substances (epitalon free base and epitalon acetate) for the 503A bulks list, evaluated for insomnia (memo dated May 12, 2026), briefing document for the Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026. Read October 10, 2026. (2026)
14. NewsFrier Levitt. FDA to remove 12 popular peptides from the Category 2 'do not compound' list. April 16, 2026. (2026)
15. NewsSnow CD, Palmer KL, Bass M. PCAC adds two more bulk drug substances for the 503A list (epitalon, semax; emideltide rejected). FDA Law Blog, July 28, 2026. (2026)